Advertisement
Strategies & Technologies Driving Drug Discovery to Market
Subscribe to Drug Discovery & Development All
View Sample

FREE Email Newsletter

DDD Update

Daily news and top headlines for drug research professionals

Allergan Reviews Meeting Requests in Valeant Takeover Bid

August 23, 2014 2:23 pm | by Linda A. Johnson, AP Business Writer | News | Comments

Botox maker Allergan Inc. is reviewing shareholder requests for a special meeting to consider replacing most of its board, a change fellow drugmaker Valeant Pharmaceuticals International Inc. is seeking as part of the hostile takeover attempt. Read more...

TOPICS:

Alabama Ruling on Drug Warnings Draws Suspicion

August 23, 2014 11:25 am | by Jay Reeves | News | Comments

Business isn't buying the Alabama Supreme Court's attempt to limit the fallout from its decision saying brand-name drugmakers can be held liable for warnings on generic medication produced by other companies. Read more...         

TOPICS:

Baxter's Hemophilia Drug Hits Phase 3 Endpoint

August 22, 2014 4:05 pm | News | Comments

Baxter International Inc. announced positive results from its Phase 3 pivotal clinical trial of BAX 855, an investigational, extended half-life recombinant factor VIII (rFVIII) treatment for hemophilia A. Read more...          

TOPICS:
Advertisement

Janssen, ViaCyte Partner on Potential Diabetes Treatment

August 22, 2014 3:55 pm | News | Comments

ViaCyte Inc., a privately held regenerative medicine company announced that it has entered into a Rights Agreement with Janssen Research & Development LLC, one of the Janssen Pharmaceutical Companies of Johnson & Johnson. Read more...   

TOPICS:

Mylan Launches First Generic Klor-Con Extended-Release Tablets

August 22, 2014 3:46 pm | News | Comments

Mylan Inc. announced that it has launched Potassium Chloride Extended-release Tablets USP, 8 mEq (600 mg) and 10 mEq (750 mg), which is the generic version of Upsher-Smith's Klor-Con. Read more...                

TOPICS:

Some Anti-Inflammatory Drugs Affect More Than Their Targets

August 22, 2014 3:41 pm | News | Comments

Researchers have discovered that three commonly used nonsteroidal anti-inflammatory drugs, or NSAIDs, alter the activity of enzymes within cell membranes. Read more...                       

TOPICS:

Pomegranate-Based Drug May Stem Alzheimer’s, Parkinson’s

August 22, 2014 3:31 pm | News | Comments

The onset of Alzheimer’s disease can be slowed and some of its symptoms curbed by a natural compound that is found in pomegranate, according to new findings. Read more...                        

TOPICS:

Combining Vaccines Boosts Polio Immunity

August 22, 2014 3:11 pm | by Lauran Neergaard, AP Medical Writer | News | Comments

New research suggests a one-two punch could help battle polio in some of the world's most remote and strife-torn regions: Giving a single vaccine shot to children who've already swallowed drops of an oral polio vaccine greatly boosted their immunity. Read more...

TOPICS:
Advertisement

Antitope, University College London Collaborate on Fully Humanized Antibodies

August 22, 2014 11:06 am | News | Comments

Antitope Ltd. and University College London are pleased to announce that they will collaborate to humanize an anti-LRG1 antibody as part of a MRC-funded translational research and product development program being undertaken by the UCL Institute of Ophthalmology. Read more...

TOPICS:

OncoGenex Says Lung Cancer Drug Trial Will Continue

August 22, 2014 11:01 am | News | Comments

OncoGenex Pharmaceuticals announced that the Phase 3 ENSPIRIT trial, evaluating custirsen in the treatment of non-small cell lung cancer, is continuing as planned per the recommendation of the Independent Data Monitoring Committee based upon completion of the first interim futility analysis. Read more...

TOPICS:

EMA Accepts Ceftolozane/Tazobactam MAA for Review

August 22, 2014 10:54 am | News | Comments

Cubist Pharmaceuticals announced that the European Medicines Agency has accepted for review the company’s Marketing Authorization Application for its investigational antibiotic ceftolozane/tazobactam for the treatment of complicated urinary tract Infections and complicated intra-abdominal infections. Read more...

TOPICS:

Mutated Polio Virus Breaches Vaccine Protection

August 22, 2014 10:48 am | News | Comments

Scientists of the University of Bonn, together with colleagues from Gabon, are reporting alarming findings: a mutated polio virus that was able to resist the vaccine protection to a considerable extent was found in victims of an outbreak in the Congo in 2010. Read more...

TOPICS:

Bioethicists Say Ebola Drugs Must be Fairly Distributed, Tested Ethically

August 22, 2014 10:42 am | News | Comments

Researchers and health authorities need to ensure that experimental drugs to treat Ebola are distributed fairly, and in the context of randomized controlled trials in collaboration with local communities and other stakeholders, according to a new Viewpoint, published in The Lancet. Read more...

TOPICS:

The Case for Orphan Drugs

August 22, 2014 10:34 am | by Louise Rozik, Editor | Articles | Comments

Neglected by the pharmaceutical industry before the Orphan Drug Act of 1983, rare diseases are now front and center in pharma R&D, with approximately one-third of all new medicines approved by the FDA in the past 5 years having been developed for the treatment of diseases that affect fewer than 200,000 Americans. Read more...

TOPICS:

AstraZeneca, Illumina Partner on Gene Sequencing

August 21, 2014 4:12 pm | News | Comments

AstraZeneca announced that it has entered into a collaboration with gene sequencing company, Illumina Inc., to develop its next generation sequencing platform for companion diagnostic tests applicable across AstraZeneca’s oncology portfolio. Read more…

TOPICS:

Pages

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading